NKG2D Receptor and Its Ligands in Host Defense

Overview of attention for article published in Cancer Immunology Research, June 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 2 news outlets
blogs: 1 blog

twitter: 7 X users
patent: 12 patents

Citations

dimensions_citation: 460 Dimensions

Readers on

mendeley: 359 Mendeley

Summary News Blogs X Patents Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

A vaccine targeting resistant tumours by dual T cell plus NK cell attack - Nature - Alert Breaking News - United States

Alert Breaking News - US, 28 May 2022

Sharma, P., Hu-Lieskovan, S., Wargo, J. A.

ASCO Reading Room | Early, But Still Noteworthy, Lung Cancer Research From ESMO Asia 2018

MedPage Today, 23 Feb 2019

Let's be honest -- phase I trials are not nearly as "sexy" as phase III trials.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.